Taysha Gene Therapies, Inc. Operating Lease Right-of-Use Assets
Taysha Gene Therapies, Inc. (TSHA) had Operating Lease Right-of-Use Assets of $6.32 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-11
- 2026-06-30: Operating Lease, Right-of-Use Asset $6.32M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $9.15M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $9.44M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $7.46M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $6.32M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $9.15M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $9.44M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $7.46M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $7.77M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $8.08M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $8.38M 10-K · filed 2026-03-19 |
| 2024-09-30 | $8.68M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $8.97M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $9.26M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $9.58M 10-K · filed 2025-02-26 |
| 2023-09-30 | $9.85M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $10.35M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $10.65M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $10.94M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |